CohBar Inc. said it appointed Philippe Calais to the board.
Previously, Calais served as the president and CEO of Isarna Therapeutics BV, a developer of oligonucleotide therapeutics.
Menlo Park, Calif.-based CohBar is a biotechnology company focused on the research and development of mitochondria-based therapeutics for age-related diseases.
